Figure 2.

Proportion of subjects achieving HbA1c < 7% in global PIONEER trials at the end of treatment. Across PIONEER trials, approximately 7 out of 10 patients achieved HbA1c < 7% with Oral semaglutide. Empa, empagliflozin; Flex, flexible; HbA1c, glycated haemoglobin; Lira, liraglutide; Met, metformin; OAD, oral anti-diabetes drug; Pbo, placebo; Sema, semaglutide; SGLT2i, sodium-glucose co-transporter 2 inhibitor; Sita, sitagliptin. *p < 0.05 for odds of achieving HbA_1c < 7.0% with oral semaglutide vs. placebo or active comparator. ^†Primary endpoint in PIONEER 7, subjects achieving HbA_1c < 7.0%. ^‡p < 0.05 for odds of achieving HbA_1c < 7.0% with sitagliptin 100 mg vs. oral semaglutide 3 mg